JP Morgan Chase’s Immunomedics Inc IMMU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-1,135,108
| Closed | -$96.8M | – | 6175 |
|
|
2020
Q3 | $96.8M | Sell |
1,135,108
-285,241
| -20% | -$14.4M | 0.02% | 711 |
|
|
2020
Q2 | $50.3M | Buy |
1,420,349
+981,273
| +223% | +$28.7M | 0.01% | 883 |
|
|
2020
Q1 | $5.92M | Sell |
439,076
-152,348
| -26% | -$2.56M | ﹤0.01% | 2125 |
|
|
2019
Q4 | $12.5M | Buy |
591,424
+143,965
| +32% | +$2.54M | ﹤0.01% | 1937 |
|
|
2019
Q3 | $5.93M | Sell |
447,459
-42,884
| -9% | -$630K | ﹤0.01% | 2558 |
|
|
2019
Q2 | $6.79M | Buy |
490,343
+66,135
| +16% | +$995K | ﹤0.01% | 2405 |
|
|
2019
Q1 | $8.15M | Buy |
424,208
+374,510
| +754% | +$6.04M | ﹤0.01% | 2226 |
|
|
2018
Q4 | $709K | Buy |
49,698
+6,673
| +16% | +$132K | ﹤0.01% | 3945 |
|
|
2018
Q3 | $896K | Buy |
43,025
+8,811
| +26% | +$209K | ﹤0.01% | 3988 |
|
|
2018
Q2 | $810K | Buy |
34,214
+11,123
| +48% | +$224K | ﹤0.01% | 3939 |
|
|
2018
Q1 | $338K | Buy |
23,091
+1,039
| +5% | +$17K | ﹤0.01% | 4178 |
|
|
2017
Q4 | $356K | Buy |
+22,052
| New | +$260K | ﹤0.01% | 4216 |
|
|
2016
Q3 | – | Sell |
-794
| Closed | -$2K | – | 4942 |
|
|
2016
Q2 | $2K | Hold |
794
| – | – | ﹤0.01% | 4629 |
|
|
2016
Q1 | $2K | Sell |
794
-729
| -48% | -$1.64K | ﹤0.01% | 4525 |
|
|
2015
Q4 | $5K | Buy |
+1,523
| New | +$4.25K | ﹤0.01% | 4359 |
|
|
2013
Q4 | – | Sell |
-19,071
| Closed | -$118K | – | 4309 |
|
|
2013
Q3 | $118K | Sell |
19,071
-87
| -0.5% | -$501 | ﹤0.01% | 4150 |
|
|
2013
Q2 | $104K | Buy |
+19,158
| New | +$62.9K | ﹤0.01% | 4147 |
|
JP Morgan Chase's IMMU Position: Q4 2020 in Review
JP Morgan Chase sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 1,135,108 shares — an estimated $96.8M sold.
JP Morgan Chase first reported a position in IMMU in Q2 2013 and held it in 17 quarters. The position peaked at $96.8M in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.
- JP Morgan Chase reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
- JP Morgan Chase sold 1,135,108 Immunomedics Inc shares in Q4 2020, an estimated $96.8M.
- JP Morgan Chase first reported a position in Immunomedics Inc in Q2 2013 and held it in 17 quarters.
- JP Morgan Chase's Immunomedics Inc position peaked at $96.8M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.
Based on JP Morgan Chase's 13F filing for Q4 2020, filed 11 Feb 2021.